Killingworth, CT, United States of America

Donald R O'Boyle, Ii

USPTO Granted Patents = 2 

Average Co-Inventor Count = 16.1

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2012-2016

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Donald R O'Boyle, II

Introduction

Donald R O'Boyle, II is a notable inventor based in Killingworth, CT (US). He has made significant contributions to the field of antiviral compounds, particularly in the fight against Hepatitis C virus (HCV). With a total of 2 patents, his work has the potential to impact the medical community significantly.

Latest Patents

O'Boyle's latest patents focus on innovative approaches to combat Hepatitis C. The first patent, titled "Hepatitis C virus inhibitors," is directed towards antiviral compounds that inhibit the function of the NS5A protein encoded by HCV. This patent outlines compositions comprising combinations of these compounds and methods for their application. The second patent, "Inhibitors of HCV replication," describes compounds that can inhibit HCV replication, specifically targeting the function of the HCV NS5A protein.

Career Highlights

O'Boyle is currently associated with Bristol-Myers Squibb Company, where he continues to develop groundbreaking solutions in the pharmaceutical industry. His work is crucial in advancing treatments for viral infections, showcasing his dedication to improving public health.

Collaborations

Some of his notable coworkers include Nicholas A Meanwell and Makonen Belema, who contribute to the innovative environment at Bristol-Myers Squibb Company.

Conclusion

Donald R O'Boyle, II exemplifies the spirit of innovation in the pharmaceutical field, with his patents paving the way for new treatments against Hepatitis C. His contributions are vital in the ongoing battle against viral infections, and his work continues to inspire future advancements in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…